Insulet Corporation to Present at Upcoming Investor Conferences

Feb 28, 2018

Insulet Corporation to Present at Upcoming Investor Conferences

BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 28, 2018-- Insulet Corporation (NASDAQ:PODD) (Insulet), the leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at three upcoming investor conferences:

This press release features multimedia. View the full release here:

  • The Raymond James & Associates’ 39th Annual Institutional Investors Conference in Orlando, Florida on Monday, March 5, 2018 at 11:00 a.m. (Eastern Time).
  • The Cowen and Company 38th Annual Health Care Conference in Boston, Massachusetts on Monday, March 12, 2018 at 12:00 p.m. (Eastern Time).
  • The Barclays Global Healthcare Conference in Miami, Florida on Tuesday, March 13, 2018 at 9:30 a.m. (Eastern Time).

To listen to live audio webcasts of the presentations, please visit Replays of the webcasts will also be available following the events.

About Insulet Corporation:

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit:, and*

*Starting July 1, 2018, Insulet will assume direct distribution of its Omnipod Insulin Management System in Europe, including sales, marketing, training and customer support activities. This will allow Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as it already does in the United States and Canada.

Source: Insulet Corporation

Investor Relations and Media Contact:
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications